Due to substantial increases in the use of healthcare resources, medical costs in the U.S. for people with amyotrophic lateral sclerosis (ALS) rise significantly as the disease progresses, going from about $31,000 per year in the early disease stage to $122,000 per year in the late stage, a study…
Healthcare costs increase as ALS progresses, Biogen study finds
The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is amending its master protocol to allow a longer follow-up time and collection of blood cells for use in future research. Slight modifications to the enrollment criteria and visit schedule will…
In the field next to our home, a stand of more than 100 Fraser firs provide boughs for my wreath-making operation. It’s a good seasonal gig for me because it’s flexible. Since I take care of my husband, Todd, who is paralyzed due to ALS, I can’t work outside…
Neurosense Therapeutics is working on finishing touches for the protocol of a Phase 3 study testing PrimeC, an oral treatment the company is developing for amyotrophic lateral sclerosis (ALS), and plans to submit the protocol for approval to the U.S. Food and Drug Administration (FDA) in the first…
The Centers for Medicare and Medicaid Services (CMS) has issued a directive requiring that Medicare Advantage plans cover Qalsody (tofersen) to treat people with amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene. The directive comes after the ALS Association worked closely with…
Dazucorilant, an oral cortisol modulator being developed by Corcept Therapeutics, didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) over a placebo, meaning it failed to meet the primary goal of the DAZALS Phase 2 clinical trial. The study (NCT05407324), which tested dazucorilant doses…
Bravyl (oral fasudil), an experimental therapy Woolsey Pharmaceuticals is developing for amyotrophic lateral sclerosis (ALS), significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of the disease. New data was presented at the University of Denver during the International Symposium on ALS/MND, which took…
One of the things I cherished most about my late husband, Jeff, was his love of the holidays. From the year we began dating until our last Christmas, before he died from ALS in 2020, Jeff made the holidays special. During this season, he exuded a childlike glee that…
Specialists diagnose amyotrophic lateral sclerosis (ALS) twice as fast as general neurologists, research led by the ALS Association in collaboration with leading ALS clinicians shows. The average time for ALS or neuromuscular specialists to diagnose ALS…
It’s been a rough season lately in terms of finding care for my husband, Todd. One of his long-term nighttime caregivers gave notice last summer about moving on. Not only did she work two nights per week, but she was also flexible enough to pick up additional shifts, even on…
Recent Posts
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple
- Tossing and turning over fears this ALS journey has come to its end
- Experimental ALS therapy QRL-201 shows potential to slow disease decline
- Worried about an inability to multitask? Here’s what helped me.